GO:0010760 negative regulation of macrophage chemotaxis: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010760 describes any process that decreases the rate, frequency or extent of macrophage chemotaxis, the directed movement of a macrophage toward an external stimulus.
• Negative regulation of macrophage chemotaxis is a brake on inflammation: it restrains excessive myeloid infiltration into tumors, ischemic myocardium, adipose tissue and other inflamed sites.
• The E3 ubiquitin ligase Cop1 was identified in vivo as a modulator of macrophage infiltration and a cancer immunotherapy target, directly linking negative regulation of chemotaxis to tumor immunity.
• DHX34 acts as a negative regulator of the CX3CL1-CX3CR1 axis, reducing macrophage recruitment and CD8+ T-cell infiltration in hepatocellular carcinoma.
• Wip1 (PPM1D) modulates macrophage migration and phagocytosis, providing a phosphatase-dependent mechanism for dampening chemotactic responses.
• Studying this process requires combined CRISPR knockout, knock-in, overexpression and chemotaxis assays, supported by RNA-seq, imaging and cytokine profiling.
Description
Macrophages are innate immune cells that navigate tissues in response to chemokine gradients, a process termed macrophage chemotaxis. GO:0010760, negative regulation of macrophage chemotaxis, captures the biological processes that decrease the rate, frequency or extent of this directed migration. Because macrophage infiltration is a central driver of tumor progression, ischemia-reperfusion injury and metabolic inflammation, understanding the molecular brakes on chemotaxis is essential for therapeutic development.
negative regulation of macrophage chemotaxis At A Glance
| GO ID | GO:0010760 |
|---|---|
| GO term | negative regulation of macrophage chemotaxis |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency or extent of macrophage chemotaxis |
| Process regulated | Macrophage chemotaxis (movement of a macrophage in response to an external stimulus) |
| Biological context | Inflammation resolution, tumor immune microenvironment, tissue injury |
| Representative regulators | Cop1, DHX34, Wip1 (PPM1D), CB1 receptor signaling |
| Disease relevance | Cancer immunotherapy, myocardial ischemia/reperfusion injury, obesity-associated inflammation |
What Is GO:0010760?
GO:0010760 is a biological_process term defined as any process that decreases the rate, frequency or extent of macrophage chemotaxis. Macrophage chemotaxis itself is the movement of a macrophage in response to an external stimulus. In practical terms, negative regulators of macrophage chemotaxis are molecules or pathways that suppress the sensing of, or response to, chemoattractant gradients, thereby limiting macrophage recruitment into tissues.
Why Is negative regulation of macrophage chemotaxis Important in Cell Biology?
Negative regulation of macrophage chemotaxis is important because unrestrained macrophage recruitment amplifies tissue damage and tumor immunosuppression. In vivo CRISPR screens identified Cop1 as a modulator of macrophage infiltration and a cancer immunotherapy target, showing that negative regulators of chemotaxis can be therapeutically exploited. Similarly, DHX34 restrains the CX3CL1-CX3CR1 axis and limits CD8+ T-cell infiltration in hepatocellular carcinoma, linking chemotaxis brakes to adaptive immunity. In myocardial ischemia/reperfusion injury, IL-34-NF-kB signaling aggravates injury by facilitating macrophage recruitment and polarization, underscoring the need to understand endogenous negative regulators.
• Limits excessive macrophage infiltration into tumors, shaping the immune microenvironment and immunotherapy response.
• Restrains macrophage recruitment in myocardial ischemia/reperfusion injury, where IL-34-NF-kB signaling drives damage.
• Controls adipose tissue macrophage polarization and chemotaxis during diet-induced obesity, with microRNA involvement.
• Modulates the CX3CL1-CX3CR1 axis and CD8+ T-cell infiltration in hepatocellular carcinoma.
• Provides phosphatase-dependent braking of migration and phagocytosis through Wip1 (PPM1D).
• Defines M1 versus M2 macrophage gene signatures that include chemotaxis-related programs.
• Is relevant to idiopathic inflammatory myopathy, where muscle tissue cell diversity includes macrophage populations.
• Offers druggable nodes such as E3 ligases and kinases for anti-inflammatory and immuno-oncology strategies.
What Happens During negative regulation of macrophage chemotaxis?
Sensing and dampening chemoattractant gradients
In simple terms: Macrophages follow chemical trails, and negative regulators make them less responsive to those trails.
Macrophage chemotaxis begins with detection of external stimuli such as chemokines. Negative regulation of this process reduces the sensitivity or signaling strength of chemoattractant receptors. DHX34 acts as a negative regulator of the CX3CL1-CX3CR1 axis, reducing macrophage recruitment in hepatocellular carcinoma. This illustrates how a single RNA helicase can dampen a chemokine-receptor circuit and thereby limit macrophage chemotaxis.
Ubiquitin-dependent control of infiltration
In simple terms: Tagging proteins for degradation can put the brakes on macrophage movement.
In vivo CRISPR screens identified the E3 ligase Cop1 as a modulator of macrophage infiltration and a cancer immunotherapy target. Cop1-mediated ubiquitination provides a post-translational mechanism that can negatively regulate the extent of macrophage chemotaxis and tissue infiltration, making it a tractable node for immunotherapy.
Phosphatase-dependent braking of migration
In simple terms: Enzymes that remove phosphate groups can slow macrophage movement.
Wip1 (PPM1D) is a phosphatase that modulates macrophage migration and phagocytosis. By dephosphorylating signaling intermediates, Wip1 can attenuate the intracellular cascades that drive chemotaxis, representing a negative regulatory layer that restrains macrophage motility.
Cytokine and receptor signaling that recruits macrophages
In simple terms: Some cytokines call macrophages in, and blocking them is a form of negative regulation.
Interleukin-34-NF-kB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization. Negative regulation of macrophage chemotaxis therefore includes interference with cytokine-receptor pathways that would otherwise promote recruitment, and targeting these pathways can reduce injury.
MicroRNA and metabolic control of chemotaxis
In simple terms: Small RNAs and metabolic signals can tune how many macrophages arrive.
MicroRNAs participate in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity. This demonstrates that negative regulation of macrophage chemotaxis can be exerted at the post-transcriptional level and is sensitive to metabolic state, linking obesity-associated inflammation to chemotaxis control.
Key Genes Involved in GO:0010760 negative regulation of macrophage chemotaxis
The following genes and proteins have been experimentally linked to negative regulation of macrophage chemotaxis or to the chemotactic programs it restrains.
| Gene | Major Role | Research Relevance |
|---|---|---|
| COP1 | E3 ubiquitin ligase modulating macrophage infiltration | In vivo CRISPR screen target for cancer immunotherapy |
| DHX34 | Negative regulator of the CX3CL1-CX3CR1 axis | Reduces macrophage recruitment and CD8+ T-cell infiltration in HCC |
| PPM1D (Wip1) | Phosphatase modulating macrophage migration and phagocytosis | Dephosphorylation-dependent braking of motility |
| CX3CR1 | Chemokine receptor for CX3CL1 | Axis dampened by DHX34 in hepatocellular carcinoma |
| CX3CL1 | Chemokine ligand for CX3CR1 | Recruitment signal restrained by negative regulators |
| IL34 | Cytokine promoting macrophage recruitment and polarization | Aggravates myocardial ischemia/reperfusion injury |
| NFKB1 | Transcription factor downstream of IL-34 signaling | Mediates macrophage recruitment in ischemic injury |
| CNR1 (CB1) | Cannabinoid receptor influencing adipose macrophage polarization | CB1 antagonist regulates chemotaxis in obesity |
| AR | Androgen receptor influencing tumor immune microenvironment | Enzalutamide resistance alters immunosuppressive macrophage states |
| CCL2 | Chemokine recruiting macrophages | General chemotaxis axis relevant to negative regulation studies |
| CCR2 | Receptor for CCL2 on macrophages | Chemotaxis receptor whose signaling can be dampened |
| TNF | Pro-inflammatory cytokine shaping M1 macrophage signatures | M1 versus M2 gene signature context |
| IL10 | Anti-inflammatory cytokine associated with M2 macrophages | M2 polarization and chemotaxis programs |
| CD8A | T-cell marker influenced by macrophage recruitment | Linked to DHX34-CX3CL1-CX3CR1 axis in HCC |
| PTPRC (CD45) | Pan-leukocyte marker | Used to identify macrophage infiltration in tissues |
| ADGRE1 (F4/80) | Macrophage marker in mice | Used in chemotaxis and infiltration assays |
| ITGAM (CD11b) | Integrin involved in macrophage adhesion and migration | Migration and infiltration readouts |
How Is negative regulation of macrophage chemotaxis Regulated?
Negative regulation of macrophage chemotaxis is itself regulated at multiple levels. Post-translational control by the E3 ligase Cop1 modulates macrophage infiltration and is exploitable for immunotherapy. Phosphatase activity of Wip1 (PPM1D) restrains migration and phagocytosis. Cytokine signaling through IL-34 and NF-kB promotes recruitment, so interference with this axis acts as a negative regulatory input. Post-transcriptional control by microRNAs participates in CB1 antagonist-mediated regulation of adipose tissue macrophage chemotaxis. Together, these layers tune the balance between macrophage recruitment and restraint.
negative regulation of macrophage chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| COP1 | Cancer immunotherapy and macrophage infiltration | Cop1 knockout or overexpression in macrophage cell lines with chemotaxis assays |
| DHX34 | Hepatocellular carcinoma and CX3CL1-CX3CR1 axis | DHX34 knockout macrophages co-cultured with HCC cells |
| IL34 | Myocardial ischemia/reperfusion injury | IL-34 gain- and loss-of-function in cardiac injury models |
| PPM1D (Wip1) | Macrophage migration and phagocytosis | Wip1 knockout or phosphatase-dead knock-in macrophages |
| CNR1 (CB1) | Obesity-associated adipose tissue inflammation | CB1 antagonist treatment with microRNA profiling in obese models |
Cancer and the tumor immune microenvironment
Negative regulators of macrophage chemotaxis shape tumor immunity. Cop1 was identified in vivo as a modulator of macrophage infiltration and a cancer immunotherapy target, indicating that dampening chemotaxis can be therapeutically leveraged. In hepatocellular carcinoma, DHX34 negatively regulates the CX3CL1-CX3CR1 axis and reduces CD8+ T-cell infiltration, linking chemotaxis brakes to adaptive immune exclusion. In prostate cancer, androgen receptor blockade resistance with enzalutamide results in immunosuppressive alterations in the tumor immune microenvironment, including macrophage states.
Myocardial ischemia/reperfusion injury
Interleukin-34-NF-kB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization. This demonstrates that when negative regulation of macrophage chemotaxis is insufficient, excessive macrophage influx worsens cardiac injury, making chemotaxis-restraining pathways attractive therapeutic targets.
Obesity-associated metabolic inflammation
MicroRNAs mediate CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity. This connects negative regulation of macrophage chemotaxis to metabolic disease and suggests that chemotaxis control in adipose tissue can be pharmacologically modulated.
Inflammatory myopathy and tissue macrophage diversity
Characterization of muscle tissue cell diversity in idiopathic inflammatory myopathy has revealed distinct macrophage populations relevant to inflammatory tissue damage. Understanding negative regulation of macrophage chemotaxis in muscle may inform how macrophage infiltration contributes to myopathy pathology.
From negative regulation of macrophage chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene a negative regulator of macrophage chemotaxis? | CRISPR knockout in macrophage cell lines followed by transwell chemotaxis assays |
| Does a specific phosphorylation site control chemotaxis braking? | Point-mutation knock-in of phospho-dead or phospho-mimetic residues |
| Does a disease-associated variant alter chemotaxis? | Knock-in of the variant allele in macrophages with migration readouts |
| Where and when is the regulator expressed during infiltration? | Tagged knock-in with fluorescent reporter and live imaging |
| Does forced expression of a negative regulator reduce infiltration? | Overexpression of the candidate gene in macrophages or tumor models |
| Which pathways cooperate to restrain chemotaxis? | CRISPR library screening combined with RNA-seq and bioinformatics |
How to Study the negative regulation of macrophage chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis assay | Rate and extent of macrophage migration | Testing negative regulators of chemotaxis |
| Live-cell imaging | Directional movement and speed | Visualizing chemotaxis braking in real time |
| In vivo CRISPR screen | Genes modulating macrophage infiltration | Identifying immunotherapy targets such as Cop1 |
| RNA-seq | Transcriptional signatures of macrophage states | M1 versus M2 and chemotaxis gene programs |
| MicroRNA profiling | Post-transcriptional regulators | CB1 antagonist effects on adipose macrophages |
| Cytokine profiling | IL-34 and NF-kB pathway activity | Ischemia/reperfusion injury models |
| Phospho-proteomics | Phosphatase-dependent signaling changes | Wip1-mediated migration control |
| Immunohistochemistry | Tissue macrophage infiltration | Tumor and muscle tissue analysis |
Transwell and live-imaging chemotaxis assays
Transwell migration assays and live imaging quantify the rate and extent of macrophage movement toward chemoattractants. These assays are the direct functional readout for negative regulation of macrophage chemotaxis and are used to test candidate regulators such as Cop1 and Wip1.
CRISPR screening and functional genomics
In vivo CRISPR screens can identify modulators of macrophage infiltration, as demonstrated for the E3 ligase Cop1. Pooled screens combined with bioinformatics prioritize negative regulators whose loss increases chemotaxis, providing causal evidence for GO:0010760.
Transcriptomic and microRNA profiling
RNA-seq and microRNA profiling reveal gene signatures associated with M1 versus M2 macrophage polarization and chemotaxis programs. These approaches identify post-transcriptional regulators, such as microRNAs involved in CB1 antagonist-mediated chemotaxis control.
Cytokine and phospho-signaling analysis
Measuring cytokines such as IL-34 and NF-kB pathway activation, as well as phosphatase-dependent phosphorylation events, clarifies how signaling cascades are dampened during negative regulation of macrophage chemotaxis.
How CRISPR Can Be Used to Study GO:0010760 negative regulation of macrophage chemotaxis
Knockout
CRISPR knockout of candidate genes such as COP1, DHX34 or PPM1D in macrophages allows direct testing of whether loss of function increases chemotaxis, thereby confirming a negative regulatory role in GO:0010760.
Point Mutation
Point-mutation knock-in can dissect specific residues required for negative regulation, for example phosphatase-dead mutants of Wip1 or phospho-site mutants in signaling intermediates that control macrophage migration.
Knock-in
Knock-in of reporters or disease-associated variants enables tracking of regulator expression during infiltration and testing of whether a variant alters chemotaxis in hepatocellular carcinoma or other disease contexts.
Overexpression
Overexpression of negative regulators such as Cop1 or DHX34 can suppress macrophage chemotaxis and reduce infiltration, providing gain-of-function evidence and a basis for therapeutic strategies in cancer and ischemic injury.
How EDITGENE Supports negative regulation of macrophage chemotaxis Research
Researchers studying negative regulation of macrophage chemotaxis-related genes often need to determine whether a candidate gene is causally involved in restraining macrophage migration, and which domains or residues mediate that brake. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of macrophage chemotaxis research.
Frequently Asked Questions About negative regulation of macrophage chemotaxis
What is negative regulation of macrophage chemotaxis (GO:0010760)?
It is any biological process that decreases the rate, frequency or extent of macrophage chemotaxis, which is the movement of a macrophage in response to an external stimulus.
What genes are involved in negative regulation of macrophage chemotaxis?
Reported regulators include COP1, an E3 ligase modulating macrophage infiltration, DHX34, a negative regulator of the CX3CL1-CX3CR1 axis, and PPM1D (Wip1), a phosphatase controlling migration and phagocytosis.
How does Cop1 regulate macrophage chemotaxis?
In vivo CRISPR screens identified Cop1 as a modulator of macrophage infiltration and a cancer immunotherapy target, indicating ubiquitin-dependent control of chemotaxis.
Why is negative regulation of macrophage chemotaxis important in cancer?
It restrains excessive macrophage infiltration and shapes the tumor immune microenvironment, influencing immunotherapy responses.
What role does DHX34 play in macrophage recruitment?
DHX34 acts as a negative regulator of the CX3CL1-CX3CR1 axis and reduces macrophage recruitment and CD8+ T-cell infiltration in hepatocellular carcinoma.
How is Wip1 involved in macrophage migration?
Wip1 (PPM1D) is a phosphatase that modulates macrophage migration and phagocytosis, providing a dephosphorylation-dependent brake on motility.
Which diseases are linked to defective negative regulation of macrophage chemotaxis?
Cancer, myocardial ischemia/reperfusion injury, obesity-associated adipose inflammation and inflammatory myopathy have been linked to macrophage recruitment and chemotaxis control.
What methods are used to study negative regulation of macrophage chemotaxis?
Transwell chemotaxis assays, live imaging, in vivo CRISPR screens, RNA-seq, microRNA profiling and cytokine analysis are commonly used.
Can CRISPR knockout help identify negative regulators of chemotaxis?
Yes, CRISPR knockout of candidate genes followed by chemotaxis assays can confirm whether a gene restrains macrophage migration.
How do microRNAs affect macrophage chemotaxis in obesity?
MicroRNAs participate in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity.
Conclusion
GO:0010760, negative regulation of macrophage chemotaxis, defines the molecular brakes that limit macrophage recruitment in tumors, injured myocardium, adipose tissue and inflammatory muscle disease. Key regulators such as Cop1, DHX34 and Wip1 demonstrate that chemotaxis restraint is genetically encoded and therapeutically actionable. Combining CRISPR knockout, knock-in, point-mutation and overexpression models with chemotaxis assays and bioinformatics provides a rigorous path to dissect these mechanisms and translate them into new treatments.
References
- 1. Wang X et al.. 2021. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.. Cell 184(21):5357-5374.e22 PMID: 34582788
- 2. Orecchioni M et al.. 2019. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages.. Front Immunol 10:1084 PMID: 31178859
- 3. Zhuang L et al.. 2023. Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization.. EBioMedicine 95:104744 PMID: 37556943
- 4. Xu P et al.. 2023. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.. J Immunother Cancer 11(5) PMID: 37147019
- 5. Mehrpouya-Bahrami P et al.. 2019. Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity.. J Biol Chem 294(19):7669-7681 PMID: 30910812
- 6. Zhu H et al.. 2025. Characterization of Muscle Tissue Cell Diversity and Clinical Implications in Idiopathic Inflammatory Myopathy.. J Cachexia Sarcopenia Muscle 16(5):e70043 PMID: 40874258
- 7. Li Z et al.. 2026. Macrophage DHX34 as a negative regulator of the CX3CL1-CX3CR1 axis and CD8(+) T-cell infiltration in hepatocellular carcinoma.. Int Immunopharmacol 169:116014 PMID: 41389669
- 8. Tang Y et al.. 2017. Wip1-dependent modulation of macrophage migration and phagocytosis.. Redox Biol 13:665-673 PMID: 28822916
